Mr. Marc-Andre Massue reports

DIAGNOS ANNOUNCES DATE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS

Diagnos Inc.'s 2024 annual general and special meeting of shareholders will be held on Sept. 25, 2024, at 10 a.m.

Purposes of the meeting:

1. To receive the annual report of management, the audited consolidated financial statements of the corporation for the financial year ended March 31, 2024, and the independent auditor's report thereon;
2. To elect the directors of the corporation;
3. To reappoint Raymond Chabot Grant Thornton LLP as the independent auditor of the corporation for the ensuing year and to authorize the directors to fix its remuneration;
4. To approve, by ordinary resolution, the amendment to the corporation's existing stock option plan in order to increase the maximum number of common shares that may be issued pursuant thereto by two million, as approved by the board of directors on Aug. 21, 2024;
5. To transact such other business as may properly come before the meeting or any adjournment thereof.

Attendance/participation at the meeting

Registered shareholders and non-registered holders (as defined in the 2024 management information circular available on SEDAR+) who do not intend to vote at the meeting are kindly asked to participate via video conferencing.

Registered shareholders and duly appointed proxyholders who intend to vote at the meeting will be able to vote in person at the corporation's head office located at 7005 Taschereau Blvd., Suite 265, Brossard, Que.

The corporation is strongly recommending all shareholders to vote by proxy in advance of the meeting.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its Flaire artificial intelligence (AI) platform. Flaire allows for quick modifying and developing of applications such as CARA (computer-assisted retina analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

We seek Safe Harbor.